Statera Biopharma Inc
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells an… Read more
Market Cap & Net Worth: Statera Biopharma Inc (STAB)
Statera Biopharma Inc (PINK:STAB) has a market capitalization of $7.14K ($7.14K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #46089 globally and #14405 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Statera Biopharma Inc's stock price $0.00 by its total outstanding shares 71416038 (71.42 Million).
Statera Biopharma Inc Market Cap History: 2015 to 2025
Statera Biopharma Inc's market capitalization history from 2015 to 2025. Data shows change from $249.24 Million to $7.14K (-67.73% CAGR).
Statera Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Statera Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.84x
Statera Biopharma Inc's market cap is 3.84 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $72.13 Million | $7.59 Million | -$3.61 Million | 9.50x | N/A |
| 2019 | $42.99 Million | $47.07 Million | -$3.35 Million | 0.91x | N/A |
| 2020 | $246.39 Million | $41.55 Million | -$13.22 Million | 5.93x | N/A |
| 2022 | $5.71 Million | $1.49 Million | -$174.41 Million | 3.84x | N/A |
Competitor Companies of STAB by Market Capitalization
Companies near Statera Biopharma Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Statera Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Statera Biopharma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Statera Biopharma Inc's market cap moved from $249.24 Million to $ 7.14K, with a yearly change of -67.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $7.14K | 0.00% |
| 2024 | $7.14K | -83.33% |
| 2023 | $42.85K | -99.25% |
| 2022 | $5.71 Million | -96.52% |
| 2021 | $164.26 Million | -33.33% |
| 2020 | $246.39 Million | +473.09% |
| 2019 | $42.99 Million | -40.40% |
| 2018 | $72.13 Million | -74.81% |
| 2017 | $286.37 Million | +182.39% |
| 2016 | $101.41 Million | -59.31% |
| 2015 | $249.24 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Statera Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.14K USD |
| MoneyControl | $7.14K USD |
| MarketWatch | $7.14K USD |
| marketcap.company | $7.14K USD |
| Reuters | $7.14K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.